Meeting report VLPNPV: Session 6: Development and characterization.
Hum Vaccin Immunother
; 10(10): 3074-6, 2014.
Article
en En
| MEDLINE
| ID: mdl-25458600
Palabras clave
APC, antigen presenting cells; CGE, capillary gel electrophoresis; CLP, core-like particle; GFP, green fluorescent protein; H7N9; HA, hemagglutinin; HAI, hemagglutination-inhibition; HBcAg; HBcAg, Hepatitis B core antigen; HIV, human immunodeficiency virus; IL-1ß, Interleukin 1ß; IM, intramuscular; IgA/IgG, Immunoglobulin A/Immunoglobulin G; MS2; NA, neuraminidase; NiV, Nipah virus; NoV, norovirus; RV VP6; RV, rotavirus; S. aureus, Staphylococcus aureus; Sf9, Spodoptera frugiperda 9; VLP; VLP, virus-like particle; VP2/VP6, Viral protein 2/Viral protein 6; WHO, World Health Organization; cGMP, current good manufacturing practices; hMTS, hollow microstructured transdermal system; mRNA, messenger RNA; sMTS, solid microstructured transdermal system
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra la Influenza
/
Sistemas de Liberación de Medicamentos
/
Vacunas contra Rotavirus
/
Vacunas de Partículas Similares a Virus
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Hum Vaccin Immunother
Año:
2014
Tipo del documento:
Article
Pais de publicación:
Estados Unidos